Crinetics | MedPath

Crinetics Pharmaceuticals Upgraded to "Buy" by Jefferies on Atumelnant Potential in CAH

4 months ago

• Jefferies upgraded Crinetics Pharmaceuticals to "Buy," citing investor concerns about Phase 2 data for atumelnant creating a buying opportunity. • The firm believes the current stock price undervalues Crinetics' potential $1B opportunity in congenital adrenal hyperplasia (CAH). • Jefferies maintains a price target of $55, suggesting confidence in atumelnant as a differentiated oral option for CAH treatment. • The analyst highlights that the market is not fully appreciating the progress Crinetics has made in the past year.

Crinetics' Atumelnant Shows Promise in Phase 2 Trial for Congenital Adrenal Hyperplasia

4 months ago

• Crinetics Pharmaceuticals' atumelnant significantly reduced key biomarkers in adults with congenital adrenal hyperplasia (CAH) in a Phase 2 trial. • The TouCAHn trial demonstrated rapid and sustained reductions in androstenedione (A4) and 17-hydroxyprogesterone (17-OHP) levels across multiple dose cohorts. • Atumelnant also improved CAH-related signs and symptoms, including testosterone normalization in women and resumption of menses in some participants. • The positive results support Crinetics' plans to advance atumelnant into Phase 3 trials for adults and Phase 2b/3 trials for pediatric patients with CAH.

FDA Accepts Crinetics' Paltusotine NDA for Acromegaly Treatment

5 months ago

• The FDA has accepted Crinetics Pharmaceuticals' NDA for paltusotine for acromegaly, setting a target action date of September 25, 2025. • If approved, paltusotine will be the first once-daily, oral somatostatin receptor type 2 agonist for acromegaly, offering an alternative to injectables. • The NDA is supported by Phase 3 trials (PATHFNDR-1 and PATHFNDR-2) demonstrating safety and efficacy in treated and untreated patients. • Paltusotine previously received Orphan Drug Designation, potentially granting market exclusivity for treating this rare condition.

Crinetics Pharmaceuticals' Atumelnant Shows Promise in Phase 2 Trial for Congenital Adrenal Hyperplasia

6 months ago

• Crinetics Pharmaceuticals' atumelnant demonstrated significant A4 reductions in a Phase 2 trial, positioning it favorably against existing treatments for congenital adrenal hyperplasia (CAH). • The trial showed a rapid onset of action for atumelnant, with substantial A4 reductions evident as early as Week 2 and sustained through Week 12, indicating potential disease-modifying capabilities. • Analysts from Morgan Stanley and Citi have maintained a Buy rating on Crinetics Pharmaceuticals' stock, citing the promising Phase 2 results and the potential for success in upcoming Phase 3 trials. • The Phase 2 trial results also indicated improvements in clinical symptoms, such as normalization of testosterone levels in female patients and resumption of menstruation, further supporting atumelnant's competitive profile.

Crinetics Reports Promising Results for Atumelnant in Treating CAH and ACTH-Dependent Cushing’s Syndrome

a year ago

Crinetics Pharmaceuticals announced positive initial findings from its Phase 2 TouCAHn study for congenital adrenal hyperplasia (CAH) and Phase 1b/2a study for ACTH-dependent Cushing’s syndrome (ADCS) at ENDO 2024. Atumelnant, a novel ACTH receptor antagonist, showed significant reductions in key biomarkers, with all participants achieving normal levels of androstenedione and cortisol, indicating its potential as an effective treatment.

Crinetics Pharmaceuticals Announces Key Developments and Appointments

5 years ago

Crinetics Pharmaceuticals has announced positive Phase 2 trial results for atumelnant in treating congenital adrenal hyperplasia, participation in the 43rd Annual J.P. Morgan Healthcare Conference, and the appointment of Isabel Kalofonos as Chief Commercial Officer. Additionally, the company has granted stock options to new employees under Nasdaq Listing Rule 5635(c)(4).